Document is current

Any future updates will be listed below

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trial

Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P12

Published Online: 2014-11-06

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark